Here is some other vaccine news of note for the week:
> In a phase 1 study, Inovio and GeneOne Life Science's MERS vaccine, dubbed INO-4700, induced high levels of antibody responses in roughly 95% of subjects and generated broad-based T-cell responses in nearly 90% of study participants. Release
> The University of Montana and startup Inimmune landed a $5.4 million grant from the NIH to develop a vaccine to fight the P. aeruginosa bacteria. Missoula Current article
> Allergy Therapeutics’ grass pollen allergy vaccine Pollinex Quattro Grass showed significant and long-lasting symptom improvements three to six years after cessation of treatment. Precision Vaccinations article